Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      Regeneron, Sanofi cut heart drug price to 4,500-6,600 dollars for Express Scripts

      Regeneron, Sanofi cut heart drug price to 4,500-6,600 dollars for Express Scripts

      Ruby Khatun Khatun3 May 2018 9:30 AM IST
      Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts Holdings Co customers in...
      Fortis Update: 2 Bidders Raise Offers to Rs 175, Rs 176 per share

      Fortis Update: 2 Bidders Raise Offers to Rs 175, Rs 176 per share

      Ruby Khatun Khatun2 May 2018 11:27 AM IST
      New Delhi: The race to acquire Fortis Healthcare has heated up with two suiters raising their offer prices for the company on the last day of the...
      Dabur Q4 profit jumps 19 percent to Rs 397 crore

      Dabur Q4 profit jumps 19 percent to Rs 397 crore

      Ruby Khatun Khatun2 May 2018 10:15 AM IST
      New Delhi: FMCG major Dabur India reported a 19.04 percent increase in consolidated net profit at Rs 397.18 crore for the fourth quarter ended March...
      Novartis says Kymriah receives second USFDA approval

      Novartis says Kymriah receives second USFDA approval

      Ruby Khatun Khatun2 May 2018 10:00 AM IST
      Swiss drugmaker Novartis said on Tuesday it received a second approval from the U.S. Food and Drug Administration (FDA) for a second form of the blood...
      Pfizer questioned on growth after sluggish Q1 sales

      Pfizer questioned on growth after sluggish Q1 sales

      Ruby Khatun Khatun2 May 2018 9:45 AM IST
      New York: Pfizer reported higher profits on Tuesday but minimal revenue growth, reviving questions about whether it will seek a large acquisition to...
      Government to demarcate stem cell therapy from stem cell drug

      Government to demarcate stem cell therapy from stem cell drug

      Ruby Khatun Khatun1 May 2018 10:59 AM IST
      New Delhi: To ensure unhindered access of 'stem cell therapy' for treatment by physicians, the Union Health Ministry has proposed to statutory...
      Biologics, research services to be main drivers of growth in FY19: Biocon

      Biologics, research services to be main drivers of growth in FY19: Biocon

      Ruby Khatun Khatun1 May 2018 10:15 AM IST
      New Delhi: Biotechnology major Biocon has said biologics and research services will continue to be the main drivers of growth for the company in the...
      Munjal-Burmans bat for level playing field in Fortis bidding

      Munjal-Burmans bat for level playing field in Fortis bidding

      Ruby Khatun Khatun1 May 2018 10:00 AM IST
      New Delhi: Hero Enterprise and Burman Family Office said that equal opportunity should be provided to all the parties involved in the bidding of...
      Govt brings ISIS drug Tramadol under narcotics law regulation

      Govt brings ISIS drug Tramadol under narcotics law regulation

      Ruby Khatun Khatun30 April 2018 12:50 PM IST
      New Delhi: Tramadol, a painkiller pharma drug, has been declared a "psychotropic substance" by the Union government and its sale in the country will...
      Sun Pharma CHC enters anti-fungal powder OTC category with ABZORB

      Sun Pharma CHC enters anti-fungal powder OTC category with ABZORB

      Ruby Khatun Khatun30 April 2018 10:51 AM IST
      Mumbai: Sun Pharma Consumer Healthcare (CHC), a division of Sun Pharmaceutical Industries Ltd announced its entry into the anti-fungal powder OTC...
      Yes Bank confident of Fortis Healthcare fetching good valuation

      Yes Bank confident of Fortis Healthcare fetching good valuation

      Ruby Khatun Khatun30 April 2018 10:30 AM IST
      Mumbai: Terming Fortis Healthcare, which is on the block, as “a very attractive asset”, its single largest shareholder Yes Bank exuded the confidence...
      Monitoring, regulating misleading ads for promoting Ayush medicine sale vital: Report

      Monitoring, regulating misleading ads for promoting Ayush medicine sale vital: Report

      Ruby Khatun Khatun30 April 2018 10:00 AM IST
      New Delhi: It is the need of the hour to strictly monitor and regulate the misleading advertisements for promoting the sale of Ayush medicine, a...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok